// App-Quantinova.ai

: A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Researchers

Presenter

  • Galina Salogub

Principal Investigators

  • Jiri Mayer

  • Frantisek Folber

  • Sebastian Grosicki

  • Aleksander B Skotnicki

  • Anna Prochwicz

  • Alexander Myasnikov

  • Alexander Gural

  • Oliver Schoenborn-Kellenberger

  • Charlie Brindley

  • Stefan Knackmuss

  • Sylvia Schwarz

  • Sandra Schmich

  • Cassandra Choe-Juliak

  • Andras Strassz

  • Leila Alland

  • Michael Doubek

Medical Centers

  • Almazov National Medical Research Centre, Saint‐Petersburg, Russian Federation

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

  • Department of Nutrition-Associated Disease Prevention, Faculty of Public Health, Medical University of Silesia, Katowice, Poland

  • University Hospital in Krakow, Krakow, Poland

  • Department of Hematology,V.A. Baranov Republican Hospital,Petrozavodsk,Russian Federation

  • Hadassah Medical Center, Jerusalem, Israel

  • Cogitars GmbH, Heidelberg, Germany

  • KinetAssist Ltd., Lanarks, United Kingdom

  • Affimed, Heidelberg, Germany

  • Pfizer Inc, New York, NY

Locations

  • Russia

  • Czech Republic

  • Poland

  • Germany

  • United Kingdom

  • United States

Companies

  • Cogitars GmbH

  • Affimed GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Cluster of Differentiation 19

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • AFM 11

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved